Cardiovascular events associated with the use of four nonselective NSAIDs (Etodolac, Nabumetone, Ibuprofen, or Naproxen) Versus a Cyclooxygenase-2 Inhibitor (Celecoxib): A population-based analysis in taiwanese adults
- 30 November 2006
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 28 (11) , 1827-1836
- https://doi.org/10.1016/j.clinthera.2006.11.009
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in TaiwanDrug Safety, 2006
- Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritisRheumatology, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Incidence of Thrombotic Cardiovascular Events in Patients Taking Celecoxib Compared with Those Taking RofecoxibDrug Safety, 2005
- A Comparison of Reported Gastrointestinal and Thromboembolic Events Between Rofecoxib and Celecoxib Using Observational DataDrug Safety, 2005
- What are the Real Lessons from Vioxx???Drug Safety, 2005
- Failing the Public Health — Rofecoxib, Merck, and the FDANew England Journal of Medicine, 2004
- Cyclooxygenase-2 InhibitorsAnesthesia & Analgesia, 2003